Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages. Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
| Website | https://initialtx.com/ |
| Employees | 13 (12 on RocketReach) |
| Founded | 2020 |
| Address | 285 E Grand Ave, South San Francisco, California 94080, US |
| Phone | +1 781-367-5419 |
| Industry | Biotechnology Research |
| Keywords | Small Molecule Drugs, Drug Discovery, Protein Aggregation, Therapeutic Development, Protein Misfolding, Biopharmaceutical, Pharmaceutical Research, Early Stage Drug Development, Drug Candidates, Biotechnology, Pharmaceutical, New Drug Modalities, Molecular Medicine, Innovative Therapeutics, Medicine Development, Precision Medicine, Disease Treatment, Clinical Development, Life Sciences |
| Competitors | Johnson & Johnson, Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences +42 more (view full list) |
Looking for a particular Initial Therapeutics employee's phone or email?
Peiwen Yu is the SVP, Discovery Biology of Initial Therapeutics.
12 people are employed at Initial Therapeutics.
Initial Therapeutics is based in South San Francisco, California.